Open AccessPROGNOSTIC SIGNIFICANCE OF REARRANGEMENTS OF EML4-ALK IN PATIENTS WITH STAGE TI-II ADENOCARCINOMA IN THE RELATIONSHIP WITH SOME CLINICAL AND MORPHOLOGICAL PARAMETERS
Author(s) -
A. M Avdalyan,
Artak U. Panas’yan,
А. А. Иванов,
O. V. Samuilenkova,
S. Yu. Bakharev,
A. S Bliznyuk,
А Ф Лазарев
Publication year - 2017
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2017-22-4-194-197
Subject(s) - adenocarcinoma , stage (stratigraphy) , medicine , immunohistochemistry , lymph , survival rate , oncology , pathology , gastroenterology , cancer , biology , paleontology
The purpose of the study: determination of ALK gene status (mutation) in patients with stage TI-II adenocarcinoma in the relationship with survival, stage, size, metastases in bronchopulmonary lymph nodes and the amplification of Her2/Neu. Materials. 98 stage I-II adenocarcinoma patients. Cases with a mutation in ALK account for 20 (4.8% without randomization). There was used the immunohistochemical method and in situ hybridization. Results. The survival rate of adenocarcinoma patients with metastases in the lymph nodes was lower than in cases without metastases: 8.3 ± 7.8% and 40.9 ± 13% respectively. None of patients with a mutation ALK lived up to 9 years in contrast to the cases without mutations (37.4 ± 12.6%). In the presence of amplification of the Her2 gene survival rate in adenocarcinoma patients was lower if compared to cases without amplification (p = 0.02). Correlation between ALK mutation and amplification of Her2 with increased N is not revealed. Thus, an independent criterion of the prognosis for cases with of stage I-II lung adenocarcinoma is the N index (χ2 = 9.6, p = 0.001). The rate of mutation of ALK was lower, but had the second largest impact on the prognosis (χ2 = 7.7, p = 0.005).